NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · page 17 of 33
The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) for the ITT population in the footer.
Pitch deck · traction · show_traction · balanced density
Slide locked Sign in to view
Slide schematic 5/5
chart 1/1 source-note 2/2 title 2/2
Components 5
line source-note source-note action-title headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.